Table 1.
Baseline patient, donor and disease characteristics at diagnosis
| Clinical parameter | MSD (n = 1891) | Haplo (n = 413) | p |
|---|---|---|---|
| Follow-up duration in m, median (range) | 24.88 (12.13;46.05) | 25.37 (13.21;42.56) | 0.92 |
| Age at transplant in years, median (range) | 37.7 (18–76.1) [27–49.5] | 37.1 (18.1–75) [25.7–51] | 0.58 |
| Year of transplant | 2015 (2012–2018) | 2016 (2012–2018) | < 0.0001 |
| Patient gender, n (%) | |||
| Male | 1129 (59.8%) | 268 (64.9%) | 0.055 |
| Female | 759 (40.2%) | 145 (35.1%) | |
| Diagnosis | |||
| Ph-neg B ALL | 616 (32.6%) | 148 (35.8%) | 0.44 |
| Ph-pos B ALL | 725 (38.3%) | 151 (36.6%) | |
| T-ALL | 550 (29.1%) | 114 (27.6%) | |
| Patient CMV status | |||
| Patient CMV negative, n (%) | 521 (28.1%) | 90 (22%) | 0.01 |
| Patient CMV positive, n (%) | 1335 (71.9%) | 319 (78%) | |
| Donor CMV status | |||
| Donor CMV negative, n (%) | 599 (33%) | 110 (27.1%) | 0.021 |
| Donor CMV positive, n (%) | 1215 (67%) | 296 (72.9%) | |
| Status at transplant | |||
| CR1 | 1575 (83.3%) | 275 (66.6%) | < 0.0001 |
| CR2 | 316 (16.7%) | 138 (33.4%) | |
| KPS at transplant, n (%) | |||
| < 90 | 397 (22.4%) | 100 (25%) | 0.27 |
| ≥ 90 | 1373 (77.6%) | 300 (75%) | |
| Missing | 121 | 13 | |
| Donor age, y median (range) | 38.5 (0.1–74) [27.5–50.5] | 38.8 (7.8–74.3) [27.1–49.3] | 0.79 |
| Donor gender | |||
| Male donor | 1033 (54.9%) | 242 (58.6%) | 0.17 |
| Female donor | 848 (45.1%) | 171 (41.4%) | |
| Donor-recipient gender matching, n (%) | |||
| Female–male | 474 (25.2%) | 110 (26.6%) | 0.54 |
| Other | 1408 (74.8%) | 303 (73.4%) | |
| MRD at transplant | |||
| Negative | 681 (67.4%) | 162 (65.3%) | 0.54 |
| Positive | 330 (32.6%) | 86 (34.7%) | |
| Missing | 880 | 165 |
KPS, Karnofsky performance status;TBI, total body irradiation; CMV, cytomegalovirus; MRD, measurable residual disease